CERo Therapeutics Holdings, Inc,an innovative immunotherapy company seeking to advance the next generation of  engineered T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying  mechanisms used by T cells, announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark Office (USPTO), and one European patent application has been allowed by  the European Patent Office, all of which significantly expand the Company’s intellectual property portfolio.

The USPTO granted U.S. Patent No. 12,291,557, titled, “CHIMERIC TIM4 RECEPTORS AND USES THEREOF” on May 6, 2025.  The granted claims cover certain design aspects of CER-1236, the Company’s lead compound.  This patent provides composition of matter protection for a chimeric TIM4 receptor comprising a TIM4 binding domain and canonical T cell signaling domains.

Additionally, the European Patent Office has allowed European Patent Application No. 1882166.7 titled, “CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE”  on May 16, 2025.  The allowed claims encompass a chimeric engulfment receptor comprising a TIM4 binding domain and TLR2 signaling domain. The allowance of this European patent application expands protection of additional design aspects of CER-1236, which have already been granted in the U.S., Japan, and China.   

Finally, the USPTO granted U.S. Patent No. 12,303,551, titled, “CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,” on May 20, 2025. This patent provides coverage for combination cellular immunotherapy compositions  and methods of use for CER-1236. The patent covers combination of a chimeric engulfment receptor CD4⁺ T cell (CD4⁺ CER-T cell) with a chimeric antigen receptor CD8⁺  T cell (CD8⁺ CAR-T cell) or T cell receptor CD8⁺ T cell (CD8⁺ TCR-T cell), and their use to treat cancer. This type of combination therapy could be an exciting avenue to complement the CER-T cell technology with other powerful anti-cancer therapies. CERo’s intellectual property portfolio now includes 9 total patent families with protection out to 2042 in the United States.

With these additional granted patents and allowed application, CER-1236 and its platform technology is supported by 18 total issued patents and allowed patent application internationally.

Chris Ehrlich, CERo Therapeutics CEO, commented, “We continue to aggressively expand our intellectual property portfolio, as it ensures CERo’s success in the market. These patents protect the core innovations of the CER-T technology that differentiate it from other cell therapies and demonstrate the true novelty of our design .  We continue to seek a robust range of patents across multiple geographies that cover this technology in general, and CER-1236 in particular. The appreciation of the novelty of the CER-T technology by the patent offices validates the innovation and therapeutic potential of this approach, and we believe that we will continue to grow the portfolio. In the near term, we anticipate updates on our clinical trial progress in AML, and the announcement of initiating human trials to treat ovarian and non-small cell lung cancers.”